National Academies Press: OpenBook

Exploring the Role of Antiviral Drugs in the Eradication of Polio: Workshop Report (2006)

Chapter: Appendix C: Workshop Agenda and Participant List

« Previous: Appendix B: Committee Biographical Sketches
Suggested Citation:"Appendix C: Workshop Agenda and Participant List." National Research Council. 2006. Exploring the Role of Antiviral Drugs in the Eradication of Polio: Workshop Report. Washington, DC: The National Academies Press. doi: 10.17226/11599.
×

Appendix C
Workshop Agenda and Participant List

November 1-2, 2005

Keck Center of the National Academies

500 Fifth Street, N.W. • Washington, D.C.

AGENDA

Tuesday, November 1, 2005

8:00 a.m.

Continental Breakfast

8:30 a.m.

Committee orientation (closed session)

9:00 a.m.

Workshop convocation and introductions −

Samuel Katz, chairman

9:30 a.m.

Polio eradication plan update

Looking ahead to the end-game: Bruce Aylward

Strategies for the OPV cessation era: Roland Sutter

Potential roles for an antiviral: Mark Pallansch

10:15 a.m.

Overview of poliovirus biology and pathogenesis

Eckard Wimmer

Suggested Citation:"Appendix C: Workshop Agenda and Participant List." National Research Council. 2006. Exploring the Role of Antiviral Drugs in the Eradication of Polio: Workshop Report. Washington, DC: The National Academies Press. doi: 10.17226/11599.
×

10:45 a.m.

Coffee Break

11:00 a.m.

Introduction to potential targets

Mutagenesis and RNAi: Raul Andino

Capsid-binding compounds: Marc Collett

Exploiting dominant inhibition: Karla Kirkegaard

Protease inhibitors: Amy Patick

12:00 p.m.

Organization of afternoon breakout sessions

12:30 p.m.

Buffet Lunch

1:30 p.m.

Breakout sessions

3:30 p.m.

Coffee Break

3:45 p.m.

Reports on breakout sessions and discussion

5:30 p.m.

Adjourn

Wednesday, November 2, 2005

8:00 a.m.

Continental Breakfast

8:30 a.m.

Organization of day 2 breakout groups

9:00 a.m.

Working breakout group discussions

1. Public Health group: How would the drug be used in eradication? Who would patients be, how would they be identified and reached? What would be the advantages and disadvantages of the potential compounds identified in day 1 for different aspects of eradication?

2. Biology group: Evaluate each of the potential antivirals: how difficult would each be to develop, how likely to elicit resistance, how long would it take to develop, what would be its possible safety issues?

3. Development group: How much would each type of antiviral cost to develop? How hard might it be to move them

Suggested Citation:"Appendix C: Workshop Agenda and Participant List." National Research Council. 2006. Exploring the Role of Antiviral Drugs in the Eradication of Polio: Workshop Report. Washington, DC: The National Academies Press. doi: 10.17226/11599.
×

 

through the approval process? Who might develop them? What are the likely timelines involved for each? What are possible sources of funding?

10:30 a.m.

Coffee Break

10:45 a.m.

Report from breakout group 1 and discussion

11:30 p.m.

Report from breakout group 2 and discussion

12:15 p.m.

Lunch

1:15 p.m.

Report from breakout group 3 and discussion

2:00 p.m.

Wrap-up: Designing and filling in a decision matrix for each compound

4:00 p.m.

Adjourn

PARTICIPANT LIST

Jim Alexander, CDC

Bruce Aylward, WHO

Debra Birnkrant, Center for Drug Evaluation and Research, FDA

Craig Cameron, Pennsylvania State University

Marc Collett, ViroDefense, Inc.

Walter Dowdle, The Task Force for Child Survival and Development

Ellie Ehrenfeld, NIAID, NIH

Diane Griffin, Johns Hopkins Bloomberg School of Public Health

Matthias Gromeier, Duke University Medical Center

Neal Halsey, Johns Hopkins Bloomberg School of Public Health

Stephen Hughes, National Cancer Institute

Kristin Kenyan, CDC

Karla Kirkegaard, Stanford University School of Medicine

Mauricio Landaverde, Pan American Health Organization

Catherine Laughlin, NIAID, NIH

Mark McKinlay, Gentara Corporation

Philip Minor, National Institute for Biological Standards and Control, UK

Suggested Citation:"Appendix C: Workshop Agenda and Participant List." National Research Council. 2006. Exploring the Role of Antiviral Drugs in the Eradication of Polio: Workshop Report. Washington, DC: The National Academies Press. doi: 10.17226/11599.
×

Akhter Molla, Abbott Laboratories

Mark Pallansch, CDC

Amy Patick, Pfizer

Olve Peersen, Colorado State University

Jane Seward, CDC

Tim Skern, Medical University of Vienna

Roland Sutter, WHO

Kimberly Thompson, Harvard School of Public Health

Linda Venczel, CDC

Margie Watkins, CDC

Jerry Winkelstein, Johns Hopkins Children’s Center

Peter Wright, Vanderbilt University School of Medicine

Staff from the National Academies Board on Life Sciences

Ann Reid, Study Director

Anne Jurkowski, Program Assistant

Fran Sharples, Director, Board on Life Sciences

Suggested Citation:"Appendix C: Workshop Agenda and Participant List." National Research Council. 2006. Exploring the Role of Antiviral Drugs in the Eradication of Polio: Workshop Report. Washington, DC: The National Academies Press. doi: 10.17226/11599.
×
Page 69
Suggested Citation:"Appendix C: Workshop Agenda and Participant List." National Research Council. 2006. Exploring the Role of Antiviral Drugs in the Eradication of Polio: Workshop Report. Washington, DC: The National Academies Press. doi: 10.17226/11599.
×
Page 70
Suggested Citation:"Appendix C: Workshop Agenda and Participant List." National Research Council. 2006. Exploring the Role of Antiviral Drugs in the Eradication of Polio: Workshop Report. Washington, DC: The National Academies Press. doi: 10.17226/11599.
×
Page 71
Suggested Citation:"Appendix C: Workshop Agenda and Participant List." National Research Council. 2006. Exploring the Role of Antiviral Drugs in the Eradication of Polio: Workshop Report. Washington, DC: The National Academies Press. doi: 10.17226/11599.
×
Page 72
Exploring the Role of Antiviral Drugs in the Eradication of Polio: Workshop Report Get This Book
×
Buy Paperback | $29.00 Buy Ebook | $23.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF
  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!